Drugs / STK-012
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05098132 | Jan 2022 → Jan 2029 expected | non-small cell lung carcinoma | Synthekine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STK-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098132 ↗ |
| Modality | Protein / enzyme biologic | “Engineered Interleukin-2 (IL-2) selective for antigen activated T cells” NCT05098132 ↗ |
| Route | Subcutaneous | “STK-012 subcutaneous (SC) as monotherapy in selected solid tumor indications” NCT05098132 ↗ |